E. H. Heinonen

1.8k total citations
38 papers, 1.3k citations indexed

About

E. H. Heinonen is a scholar working on Neurology, Pharmacology and Complementary and alternative medicine. According to data from OpenAlex, E. H. Heinonen has authored 38 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Neurology, 11 papers in Pharmacology and 8 papers in Complementary and alternative medicine. Recurrent topics in E. H. Heinonen's work include Parkinson's Disease Mechanisms and Treatments (19 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Ginkgo biloba and Cashew Applications (7 papers). E. H. Heinonen is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (19 papers), Cholinesterase and Neurodegenerative Diseases (7 papers) and Ginkgo biloba and Cashew Applications (7 papers). E. H. Heinonen collaborates with scholars based in Finland, United Kingdom and Sweden. E. H. Heinonen's co-authors include Vilho V. Myllylä, K. A. Sotaniemi, O. Mäki‐Ikola, U. K. Rinne, Risto Lammintausta, Sven Pålhagen, J. Hägglund, R. Palm, Jouni Vuorinen and Maarit Anttila and has published in prestigious journals such as Neurology, Journal of Pharmacology and Experimental Therapeutics and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

E. H. Heinonen

37 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. H. Heinonen Finland 22 760 436 188 165 155 38 1.3k
Andrzej Dekundy Germany 18 767 1.0× 1.0k 2.4× 372 2.0× 199 1.2× 144 0.9× 43 1.6k
P. Riederer Germany 19 649 0.9× 720 1.7× 512 2.7× 162 1.0× 94 0.6× 68 1.9k
W. Gsell Germany 24 342 0.5× 438 1.0× 430 2.3× 172 1.0× 114 0.7× 47 1.5k
M. A. Schwarzschild United States 14 817 1.1× 579 1.3× 574 3.1× 140 0.8× 67 0.4× 17 1.9k
Tomoyuki Kanda Japan 20 405 0.5× 472 1.1× 419 2.2× 87 0.5× 78 0.5× 34 1.3k
Bala V. Manyam United States 23 556 0.7× 311 0.7× 348 1.9× 225 1.4× 44 0.3× 41 1.8k
Irena Romańska Poland 18 188 0.2× 558 1.3× 268 1.4× 147 0.9× 49 0.3× 52 927
Nansie S. Sharpless United States 23 289 0.4× 899 2.1× 425 2.3× 359 2.2× 231 1.5× 55 1.6k
Daniel Rial Brazil 23 343 0.5× 531 1.2× 358 1.9× 104 0.6× 109 0.7× 44 1.5k
Robert Perry United Kingdom 14 355 0.5× 434 1.0× 396 2.1× 396 2.4× 458 3.0× 19 1.9k

Countries citing papers authored by E. H. Heinonen

Since Specialization
Citations

This map shows the geographic impact of E. H. Heinonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. H. Heinonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. H. Heinonen more than expected).

Fields of papers citing papers by E. H. Heinonen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. H. Heinonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. H. Heinonen. The network helps show where E. H. Heinonen may publish in the future.

Co-authorship network of co-authors of E. H. Heinonen

This figure shows the co-authorship network connecting the top 25 collaborators of E. H. Heinonen. A scholar is included among the top collaborators of E. H. Heinonen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. H. Heinonen. E. H. Heinonen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Myllylä, Vilho V., E. H. Heinonen, Jouni Vuorinen, Olavi Kilkku, & K. A. Sotaniemi. (2009). Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta Neurologica Scandinavica. 91(3). 177–182. 2 indexed citations
2.
Pålhagen, Sven, et al.. (2006). Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 66(8). 1200–1206. 206 indexed citations
3.
Haasio, Kristiina, et al.. (2002). Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects.. Journal of Neural Transmission. 109(11). 1391–1401. 35 indexed citations
4.
Haasio, Kristiina, et al.. (2001). Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. Journal of Neural Transmission. 108(1). 79–91. 30 indexed citations
5.
Pålhagen, Sven, et al.. (1998). Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology. 51(2). 520–525. 112 indexed citations
6.
Myllylä, Vilho V., et al.. (1997). Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study. Acta Neurologica Scandinavica. 95(4). 211–218. 41 indexed citations
7.
Myllylä, Vilho V., K. A. Sotaniemi, O. Mäki‐Ikola, U. K. Rinne, & E. H. Heinonen. (1996). Role of selegiline in combination therapy of Parkinson's disease. Neurology. 47(6_suppl_3). S200–9. 23 indexed citations
8.
Yavich, Leonid, Antti Haapalinna, Tarja Puumala, et al.. (1996). The systemic administration of tacrine or selegiline facilitate spatial learning in aged fisher 344 rats. Journal of Neural Transmission. 103(5). 619–626. 11 indexed citations
9.
Yavich, Leonid, Jouni Sirviö, E. H. Heinonen, & Paavo Riekkinen. (1993). The interaction of L-deprenyl and scopolamine on spatial learning/memory in rats. Journal of Neural Transmission - Parkinsons Disease and Dementia Section. 6(3). 189–197. 25 indexed citations
10.
Myllylä, Vilho V., K. A. Sotaniemi, Jouni Vuorinen, & E. H. Heinonen. (1993). Selegiline in de novo parkinsonian patients: The finnish study. Movement Disorders. 8(S1). S41–S44. 22 indexed citations
11.
Heinonen, E. H., et al.. (1993). Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. Journal of Neural Transmission - Parkinsons Disease and Dementia Section. 5(3). 193–202. 16 indexed citations
12.
Johnels, Bo, Páll Ingvarsson, Michael Matousek, G. Steg, & E. H. Heinonen. (1991). Optoelectronic movement analysis in Parkinson's disease: Effect of selegiline on the disability in de novo parkinsonian patients - a pilot study. Acta Neurologica Scandinavica. 84(S136). 40–43. 11 indexed citations
13.
Heinonen, E. H. & Risto Lammintausta. (1991). A review of the pharmacology of selegiline. Acta Neurologica Scandinavica. 84(S136). 44–59. 83 indexed citations
14.
Kaski, Markus, et al.. (1991). Treatment of epilepsy in mentally retarded patients with a slow‐release carbamazine preparation. Journal of Intellectual Disability Research. 35(3). 231–239. 6 indexed citations
15.
Myllylä, Vilho V., K. A. Sotaniemi, Jouni Vuorinen, & E. H. Heinonen. (1991). Selegiline as a primary treatment of Parkinson's disease. Acta Neurologica Scandinavica. 84(S136). 70–72. 22 indexed citations
16.
Liippo, Kari, V. Nikkanen, & E. H. Heinonen. (1990). Carboplatin and etoposide in advanced lung cancer: ? a phase I study. Cancer Chemotherapy and Pharmacology. 27(3). 229–233. 6 indexed citations
17.
Reunanen, Mauri, et al.. (1990). Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation. Epilepsy Research. 6(2). 126–133. 12 indexed citations
18.
Sivertsen, Børge, E. Dupont, B. Mikkelsen, et al.. (1989). Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurologica Scandinavica. 80. 147–152. 27 indexed citations
19.
Myllylä, Vilho V., K. A. Sotaniemi, Jukka Tuominen, & E. H. Heinonen. (1989). Selegiline as primary treatment in early phase Parkinson's disease - an interim report. Acta Neurologica Scandinavica. 80. 177–182. 33 indexed citations
20.
Gröhn, Pentti, E. H. Heinonen, P Appelqvist, et al.. (1984). Prospidin chemotherapy in recurrent head and neck carcinoma: a phase II study.. PubMed. 68(6). 915–7. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrzej Dekundy Breakdown of academic impact, for papers by P. Riederer Breakdown of academic impact, for papers by W. Gsell Breakdown of academic impact, for papers by M. A. Schwarzschild Breakdown of academic impact, for papers by Tomoyuki Kanda Breakdown of academic impact, for papers by Bala V. Manyam Breakdown of academic impact, for papers by Irena Romańska Breakdown of academic impact, for papers by Nansie S. Sharpless Breakdown of academic impact, for papers by Daniel Rial Breakdown of academic impact, for papers by Robert Perry
Rankless by CCL
2026